Photocure ASA
OSE:PHO
Photocure ASA
EPS (Diluted)
Photocure ASA
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Photocure ASA
OSE:PHO
|
EPS (Diluted)
kr0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-26%
|
CAGR 10-Years
N/A
|
|
|
V
|
Vistin Pharma ASA
OSE:VISTN
|
EPS (Diluted)
kr1
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
N
|
Navamedic ASA
OSE:NAVA
|
EPS (Diluted)
-kr1
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-13%
|
|
|
S
|
SoftOx Solutions AS
OSE:SOFTX
|
EPS (Diluted)
kr0
|
CAGR 3-Years
88%
|
CAGR 5-Years
68%
|
CAGR 10-Years
N/A
|
|
|
O
|
Oncoinvent ASA
OSE:ONCIN
|
EPS (Diluted)
-kr2
|
CAGR 3-Years
-90%
|
CAGR 5-Years
-55%
|
CAGR 10-Years
N/A
|
|
Photocure ASA
Glance View
Photocure ASA delivers transformative solutions to improve the lives of bladder cancer patients. The company is headquartered in Oslo, Oslo. The company went IPO on 2000-05-29. The company operates in the field of photodynamic diagnosis, cosmetics and treatment of acne, bladder cancer, colon cancer, as well as human papilloma virus (HPV) and precancerous lesions of the cervix. The Company’s activities comprise research, development and commercialization of pipeline projects within two segments: Cancer and Dermatology. Its brand portfolio includes: Hexvix and Cysview, for detection and management of bladder cancer; Visonac, for acne treatment; Cevira, used in HPV and precancerous lesions of the cervix treatment; and Lumacan, applied in colorectal cancer treatment. Furthermore, It owns a Photocure Technology platform, which develops photodynamic technology for diagnosis and therapy. The firm is a parent of a wholly owned entity, Photocure Inc.
See Also
What is Photocure ASA's EPS (Diluted)?
EPS (Diluted)
0.1
NOK
Based on the financial report for Sep 30, 2025, Photocure ASA's EPS (Diluted) amounts to 0.1 NOK.
What is Photocure ASA's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
-26%
Over the last year, the EPS (Diluted) growth was -85%.
